Latest Blog Entries

pres

April 21, 2017

Trump’s Deregulatory Agenda – Implications for Biopharma & Medtech Companies

0 Comments
By Nancy Bradish Myers and Anne Petruska McNickle On Jan. 30, President Trump issued what is now known as the “2-for-1” (or... Read More →
cat-cd2

November 14, 2016

Catalyst Commends FasterCures for Highlighting FDA Resource Needs

0 Comments
As the Trump transition team forms its plans for taking the reins in January, Catalyst applauds FasterCures for issuing a... Read More →
megaphone

September 19, 2016

Megaphone Moment: FDA uses Exondys 51 Accelerated Approval to Prove Regulatory Flexibility and Value of Patient Engagement

0 Comments
Nancy Bradish Myers, President Today the FDA granted its first-ever approval for a Duchenne Muscular Dystrophy (DMD) treatment; Sarepta received... Read More →
hogtied3

September 15, 2015
Back to Top
UA-64850428-1